In the Phase 3 VIVID-1 trial, patients treated with mirikizumab experienced significant improvement in clinical remission and endoscopic response at one year 2 Among those who achieved endoscopic response at one year, 88% of patients maintained endoscopic response at two years of continuous mirikizumab treatment in open-label extension 3 BASINGSTOKE, May 30, 2025 – Today, […]
The post NICE recommends mirikizumab (Omvoh ▼) for previously treated moderately to severely active Crohn’s disease 1 appeared first on Pharmafile.
